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A ngiogenesis, the growth of new capillaries £i'om pre-existing blood vessels, is a complex multi-step process in volv ing extravasa tion of plasma proteins, degradation of extra cellular matrix , endothelia l cell migration and proliferation, and ca pillary tube for-
mation. As in other organs, primary angiogeneSIs IS a prominent 
fea ture of developin g skin in e mbl'),ogenesis. In con trast, the adult 
cutaneous vascu lature is normall y quiescent, with the possible 
exception of some an giogenesis re lated to the ea rly imagen phase of 
the hair cycle . Adult skin, ho wever, retains the capacity to initiate 
a rapid neovascular response to patho logica l stimuli ; this "second-
ary" angiogenesis is prominent in many skin disorders including 
tissue repair, inflammation (e.g., psoriasis), and neoplas ia. This 
suggests that normal vascular quiescence is maint~lined by the 
dominant influence of natural angiogenic inhibi tors over angi o-
genic stimuli, whereas angiogenesis can be readily induced by 
increased local conce ntratio ns of angiogenic factors and/or upregu-
lation of their recepto rs on vascu lar endothelial cells. R.ecent 
advances in vascular biology ha ve identi fie d sOllle of the key factors 
that control vascul ar growth, providing surprising insights into the 
co mpl ex and interdependent cascades that result in enhanced skin 
vascularization . Based on this experimental progress, the followin g 
concepts might facilitate our understanding of how skin angiogen-
esis is controlled on a mol ecular level and might contt'ibute to the 
identification of new targets for future research . 
VPF/VEG F: T H E MAJOR SKIN ANGIOGENESIS FACTO R 
FOUND? 
Vascular permeabili ty fa ctor, also known as vascul ar endothelial 
growth factor (VPF/VEG F), is a 40-45 kD secreted hOlllodimeric 
glycoprotein that selectively binds to two high-afrinity tyrosin e 
kinase receptors 0 11 vascular endothelial cells. Originally identified 
as a tumo r cell-deri ved f.,cto r that indu ced vascular hypermeability 
to plasma prote ins (Seliger et ai, 1983) , VPF/VEGF was charac ter-
ized in subsequent studies as an endothelial cell-specifi c mitogen 
that induced angiogenesis in expel'il11 ental in vivo models. In a 
se ries of reports fro m this laboratory it could be shown that skin 
a ngiogenesis was in variabl y associated with enhanced expression of 
VPF/VEGF by ep idermal keratinocytes and upregulati o n of VPFI 
VEGF receptors on dermal microvessels. In particular, healing 
wounds showed earl y upregulation of VP.F/VEGF expression by 
lTI igrating keratin ocytes (Brown et ai, 1992) , an d the interval during 
w hich keratinocytes ex pressed VPF/VEGF correlated closely w ith 
chat durin g which dermal blood vessels were hyperperm eable and 
endotheli al cells were growing into the provisional fibl-in m atrix. 
Further stu di es established VPF/VEGF as a crucial angiogenesis 
factor in lesional psoriatic skin (Detmar et aI, 1994). Subsequently, 
enhanced expression of VPF/VEGF and/or its receptors has been 
fo und in the angiogenesis associated with delayed type skin hyper-
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sensitivity reactions (Brown et aI, 1995a), bullous diseases (Brown 
et aI, 1995b) , and in skin neoplasms including Kaposi's sarcom a. 
VPF/VEGF expression in the skin is induced by at least two distinct 
molecular pathways: In hyperplastic epidermis (e.g., psoriasis), 
epidermal keratinocytes release transforming growth factor-a 
w hich binds to the epidermal growth factor receptor on keratino-
cytes and, in an autocrine loop, stimulates secretion ofVPF/VEGF 
(Detmar et aI, 1994). VPF/VEGF secreted by epidermal keratino-
cytes is a potent and selective mitogen for dermal microvascular 
endothelial cells (Detmar et ai, 1995). A second pathway involves 
the induction of VPF/VEGF by tissue hypoxia and may be opera-
tive in healing wounds. The importance ofVPF/VEGF in p romot-
ing skin angiogenesis ill lIillo was recently confinued in a transgenic 
mouse model, using the human keratin 14 promoter to target 
selective overexpression of the murine VPF/VEGF gene to basal 
epidemlal keratinocytes and follicul ar outer root sheath keratino-
cytes (D etmar et ai, unpublished results) . VPF/VEGF transgenic 
mice displayed markedly enhanced skin vascularization, most 
prominently in the immediate vicinity of the areas of transgene 
expression . 
ANGIOGENIC EPIDERMIS VS. ANTIANGIOGENIC 
DERMAL MATR.IX 
There is compelling evidence that the angiogenic stimulus in 
normal and diseased skin is derived from the epidermis, not the 
dermis (Malhotra e t ai, 1989). This makes intuitive sense in t11at the 
avascular epidermis might be expected to have mechanism s for 
enhancing the dermal blood supply so as to m atch its high 
m etabolic demands associated with hyperproliferation in healing 
wounds, psoriasis , or neoplasms. As described in the previous 
paragraph, the specific endothelial cell mitogen VPF/VEGF m ost 
likely represents the m aj or angiogenic activity in human epidermis. 
Other non-endothelial cell-specific m ediators such as platelet-
derived growth factor, fibroblast growth factors, or interleukin-8 
might further enhance endothelial cell migratio n and/or prolifera-
tion, though none of these factors has been shown to directly 
induce the first step of angiogenesis, namely enhanced vascu.lar 
permeabi.lity to plasma proteins. 
T he normal dermal m atrix, in particular the basem ent m embrane 
surrounding microvascular endothelial cells, may function as a 
natural inhibitor of angiogenesis, thereby ensuring the integrity of 
the quiescent vessels in healthy skin. R ecent evidence suggests that 
thrombospondin-1 (TSP-1) , a multifunction al " m atricellul ar" pro-
tein that is produced by, among other cells, dermal microvascular 
endoth elial cell s, is a major physiological inhibitor of skin angio-
genesis. TSP-1 accumulates in the b asem ent membrane of quies-
cent vessels in nonnal skin but is absent in actively forming 
endothelial cell sprouts (Wight et ai, 1985). Furthermo re. TSP-1 
has been shown to inhibit angiogenesis in several il/. IIi/fa and ill 11 ;'10 
assay systems (Rastinejad et aI, 1989; lruela-Arispe et aI, 1991). 
TSP-1 m ediates its fun ctions by binding to m atrix proteins as well 
as to cell surface receptors and cytokin es. R obert Swerlick's 
laboratory describes in this issue (p. 215) that dermal microvascular 
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endothelial cells adhered to immobilized TSP-1 , but that TSP-l 
inhibited microvascular endothelial ceU migration . Based on a series 
of functional studies using antibodies and molecules that had been 
previously shown to interfere with binding to the various throm-
bospondin receptors, the au thors sugges t that bindin g of human 
dermal microvascular endothelial cell s to TSP-l is arg-gly-asp 
(RGD) indepe ndent and distin ct from m echanism s previously 
described for o the r ceU types , underljning the importance of 
skin-specifi c expel-im ental angiogenesis mode ls. [t is of interest that 
in creased amollnts of thrombospondin have been d etected around 
vessels within wounds during the late stages of wound closure 
(Wight et aI, 1985), possibly mediating the normalization of 
VPP/VEGF-induced wound vascularization. 
Other basement membrane macromolecules such as laminin o r 
coll agen type IV might also contribute to keep dermal e ndothelial 
cells in the quiescent state. Injury to the skin would result in 
disruption of the vascu lar basement membrane and therefore enable 
growth factor-driven endothelial cell migration. Additionally, en-
dothelial growth factors re leased in inflammation or neoplasia have 
been shown to indu ce the release of matrix-degrading enzymes 
such as endoth e lial cell-derived interstitial tissue collagenase, lead-
ing to degradation of the vascular basement membrane barrier. T hjs 
process is further promoted b y upregulation of plasmjnogen acti-
vators that generate active plasmin and there by activate matrix 
metalloproteases capable of furthe r digesting other matrix ele-
m ents. It remains to be established how non-endothelial demlal 
cell s such as pericytes , mast cell s, and fibroblasts might contribu te 
to the transition of quiescent endothelial cell s to the angiogenic 
phenotype. 
THE MULTISTEP ANGIOGENES IS CASCADE INVOLVES 
THE COAGULATION SYSTEM 
Wherever angiogenesis has been investigated, hyperpermeabili ty of 
microvessels precedes and accompanies angiogenesis, resulti.ng in 
leakage of plasma prote ins includin g clotting fa ctors such as 
fibrinogen and prothrombin (Dvorak et al. 1995) . Extravasated 
plasma proteins activate the extrinsic coagulation system, leading to 
. the gene ration of thrombin and cleavage of fibrinogen to fibrin, 
which is readily cross-linked by activated fa ctor X llIa . Fibrin is 
nlrther modifi ed by plasmin, which is generated loca lly from 
plasminogen by plasminoge n activators . Cross-linked fibrin pro-
vides a provisional matrix that supports endotheli al cell adhesion 
and migration, presumably via its RGD sequence; add itionall y, 
other RGD-containing plasma proteins such as fibrone ctin and 
vitronectin also ex travasate into the dermjs. It is of interest that 
other important regulators of angiogenesis are also involved in the 
coagulation cascade: T hrombospondin was o l;gina ll y described in 
platele t alpha g ranu les as a glycoprotein that function ed in plate le t 
aggregation and clot formation . VPF/ VEGF stimulates endothelial 
ce ll s to release von Willebrand factor and, by its pe rmeabili ty 
enhancing effect and induction of tissue factor, leads to activation o f 
the ex trinsic coagu lation system. Furth ermore, hepa rin and hepa-
rin-ljke macromolecul es participate in the angiogenesis cascade by 
inte racting w ith growth factors and growth factor receptors on 
targe t cells. T he finding that many of the fa ctors in vo lved in the 
coagu lation cascade arc also important in angiogenesis suggests that 
th ere is considerable overlap between the two systems that might 
have originated Ii-om cOl11mon fu ndal11entalmcchallism s developed 
for the purpose of tissue repair. It is tempting to speculate that, in 
analogy w ith malignant tumors (Dvorak, 1986), some inflammatory 
skill diseases slich as psoriasis may ha ve "borrowed" these funda-
mental mechanisms to induce enhanced skin vascularization. 
T H E J OURNAL OF INVESTI GAT IVE D EltMATO LOGY 
TARGET IN G SKIN ANG IOGENES IS AS A NEW 
THERAPEUTIC APPROA H ? 
At present, morc than 30 ongoing clinical tr ials arc testing angio-
genesis inhibitors to treat hum an can ce rs. Molecules currently 
be ing tested include angiostatic stero ids, sul f.,ted po lysaccharides, 
polypeptides such as platele t factor 4 and 3ngiostatin, protease 
inhibi to rs, an giostatic antibiotics (e .g. fumagillin), an tibodies to 
integrin and g rowth fa ctor receptors, as well as various other 
substances such as suramin, geni stein, and thalid omide. Efforts are 
being made to identify small no n-protein m o lecules that might 
down regulate the expression of VPF/VEGF o r inhibi t its interac-
tion with its high-affinity receptors o n tumor endothelial ceUs. 
While it is too early to assess the efficacy of these therapies in the 
control ofhul11an cancer, simi lar approachcs might be applicable to 
the treatment of skin di seases that arc charactcrized by angiogen-
esis, m ost notably inflammatory diseases includin g psoriasis (and 
possibly erythema nodosum) , Kaposi's sa rcoma , angiosarcomas and 
some severe cases of infantile hemangiomas, and metastasizing 
melanomas. In contrast, the rapcutic inductio n of angiogenesis 
might be bene ficial in the treatment of de layed wound healing or 
scleroderma. Skin may in f.,ct represent the m ost suitabl e organ 
system for angiogenesis-modu lating therapies, since topical appli-
cation of e ffectol' drugs and/or an tise nsc o li gonucleotides to spe-
cific genes might avoid potential side effects of systemic therapy and 
wou ld fac ili tate specific targeting of dermal l11i crovessels. 
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